{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:30:53Z","timestamp":1791599453949,"version":"4.3.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-04011-w","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T08:24:45Z","timestamp":1760084685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Successful treatment of osimertinib-resistant EGFR-mutant NSCLC with acquired BRAF V600E mutation using triple combination therapy: a case report with pathological confirmation"],"prefix":"10.1186","volume":"23","author":[{"given":"MingHui","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XuYu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YanBo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"issue":"9","key":"4011_CR1","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","volume":"20","author":"A Leiter","year":"2023","unstructured":"Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol. 2023;20(9):624\u201339. https:\/\/doi.org\/10.1038\/s41571-023-00798-3.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"4011_CR2","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):339\u201357. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.009.","journal-title":"Ann Oncol"},{"issue":"2","key":"4011_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1713137.","journal-title":"N Engl J Med"},{"issue":"9","key":"4011_CR4","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.3390\/pharmaceutics13091478","volume":"13","author":"F Aboubakar Nana","year":"2021","unstructured":"Aboubakar Nana F, Ocak S. Targeting BRAF activation as acquired resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small-cell lung cancer. Pharmaceutics. 2021;13(9):1478. https:\/\/doi.org\/10.3390\/pharmaceutics13091478.","journal-title":"Pharmaceutics"},{"issue":"6","key":"4011_CR5","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1634\/theoncologist.2017-0642","volume":"23","author":"L Odogwu","year":"2018","unstructured":"Odogwu L, Mathieu L, Blumenthal G, et al. FDA approval summary: Dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations. Oncologist. 2018;23(6):740\u20135. https:\/\/doi.org\/10.1634\/theoncologist.2017-0642.","journal-title":"Oncologist"},{"issue":"10","key":"4011_CR6","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","volume":"18","author":"D Planchard","year":"2017","unstructured":"Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18(10):1307\u201316. https:\/\/doi.org\/10.1016\/S1470-2045(17)30679-4.","journal-title":"Lancet Oncol"},{"key":"4011_CR7","doi-asserted-by":"publisher","unstructured":"Antonoff MB, Gay CM. Timing of local consolidative pulmonary resection for oncogene-driven stage IV lung cancer. J Thorac Cardiovasc Surg. 2025(3). https:\/\/doi.org\/10.1016\/j.jtcvs.2025.03.029.","DOI":"10.1016\/j.jtcvs.2025.03.029"},{"issue":"3","key":"4011_CR8","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jtho.2016.11.2231","volume":"12","author":"CC Ho","year":"2017","unstructured":"Ho CC, Liao WY, Lin CA, Shih JY, Yu CJ, Yang JCH. Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib. J Thorac Oncol. 2017;12(3):567\u201372. https:\/\/doi.org\/10.1016\/j.jtho.2016.11.2231.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"4011_CR9","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jtho.2018.12.038","volume":"14","author":"M Vojnic","year":"2019","unstructured":"Vojnic M, Kubota D, Kurzatkowski C, et al. Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers. J Thorac Oncol. 2019;14(5):802\u201315. https:\/\/doi.org\/10.1016\/j.jtho.2018.12.038.","journal-title":"J Thorac Oncol"},{"key":"4011_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00551","volume":"6","author":"NP Giustini","year":"2022","unstructured":"Giustini NP, Patel SP, Myall NJ, et al. Resistance to EGFR tyrosine kinase inhibitor therapy in non-small-cell lung cancer via newly acquired targetable oncogenic driver alterations with an emphasis on BRAF: case series and literature review of treatment. JCO Precis Oncol. 2022;6:e2100551. https:\/\/doi.org\/10.1200\/PO.21.00551.","journal-title":"JCO Precis Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04011-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-04011-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04011-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T08:24:48Z","timestamp":1760084688000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-04011-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4011"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-04011-w","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board (IRB) or equivalent ethics committee of the West China Xiamen Hospital of Sichuan University did not approve this study [Case Report Not required].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The subject(s) provided informed written consent for the publication of the study data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"365"}}